← Back to Search

Radiation Therapy

SBRT for Liver Cancer

Phase 2

Waitlist Available

Led By Michael Buckstein, MD, PhD

Research Sponsored by Icahn School of Medicine at Mount Sinai

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

Study Summary

This trial is testing a new way to treat liver cancer that has grown too large for other treatment methods.

Eligible Conditions

Liver Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Participants With Objective Response Rate

Secondary outcome measures

Change in Child-Turcotte-Pugh (CTP) Score

Number of Participants With Overall Survival (OS)

Progression Free Survival (PFS)

+2 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Participants with HCCExperimental Treatment2 Interventions

Participants with HCC with a lesion greater than 3 cm treated with TACE/SBRT combination

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

SBRT

2014

Completed Phase 2

~1060

TACE

2010

Completed Phase 3

~2190

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Icahn School of Medicine at Mount SinaiLead Sponsor

857 Previous Clinical Trials

524,239 Total Patients Enrolled

3 Trials studying Liver Cancer

1,550 Patients Enrolled for Liver Cancer

Michael Buckstein, MD, PhDPrincipal Investigator - Icahn School of Medicine at Mount Sinai

Icahn School of Medicine at Mount Sinai

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still opportunities to join this research project?

"Yes, this study is looking for participants right now. The listing on clinicaltrials.gov says that the trial was first posted on November 1st, 2014 and last updated on November 25th, 2020."

Answered by AI

Is TACE a low-risk procedure for people?

"TACE was given a 2 on our safety scale at Power. This is due to the fact that TACE is only in Phase 2 clinical trials, meaning while there is some data supporting its safety, there is currently no evidence of efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma

Michael Buckstein 2014. "Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02513199.